Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Director departure
ChemoCentryx, Inc. (CCXI) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/20/2022 8-K Quarterly results
10/18/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/04/2022 8-K Quarterly results
07/05/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
02/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/12/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Positive Recommendation for Use of TAVNEOS ™ in ANCA Vasculitis Adopted by European Medicines Agency Committee for Medicinal Products for Human Use"
10/12/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Offer Letter between the Company and Rita I. Jain",
"ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer"
10/08/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"ChemoCentryx Announces FDA Approval of TAVNEOS TM in ANCA-Associated Vasculitis"
09/27/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
07/06/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis"
05/24/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
03/08/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
12/21/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate"
11/09/2020 8-K Quarterly results
Docs: "ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights"
11/04/2020 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
10/28/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa"
09/01/2020 8-K Entry into a Material Definitive Agreement  Interactive Data
08/10/2020 8-K Quarterly results
06/11/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share CCXI The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Ru...",
"Underwriting Agreement, by and among ChemoCentryx, Inc. and SVB Leerink LLC and Piper Sandler & Co., as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP",
"ChemoCentryx Announces Proposed Public Offering of Common Stock",
"ChemoCentryx Prices Public Offering of Common Stock"
05/28/2020 8-K Submission of Matters to a Vote of Security Holders
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 of the Securities Exchange Act of 1934 Date of Report : May 21, 2020 ChemoCentryx, Inc. Delaware 001-35420 94-3254365 850 Maude Avenue, Mountain View, CA 94043 Registrant's telephone number, including area code: 210-2900"
05/18/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share CCXI The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Ru...",
"ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis"
05/14/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy